MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 11, 2026
TickeronGET DAILY SIGNALS
Glass House Brands (GLAS): Assessing the Path to the $9 Analyst Target

Glass House Brands (GLAS): Assessing the Path to the $9 Analyst Target

Key Takeaways

  • The central stock price target of $9.00 represents the average of three current firm-level targets: Lake Street at $7, ATB Cormark at $12, and Canaccord Genuity at $8.
  • With shares near $1.90, a move to $9 implies a gain of roughly 370% — a substantial advance rather than a modest recovery.
  • The analyst price target range is wide ($7 to $12), highlighting differing views following the October sell-off.
  • Key supports include low-cost greenhouse cultivation, a 1.0 million-pound biomass production goal, and potential U.S. cannabis rescheduling.
  • Major risks involve California wholesale price pressure, ongoing losses, federal tax rules, and possible dilution.
  • The stock declined after mixed preliminary Q3 results, which led to several target reductions from higher prior levels.
  • For additional context, review Glass House Brands' Major News, Today's Price Move, Forecast, and Earnings pages.

Current Analyst Targets and Consensus

Coverage remains limited, which gives each individual call more influence. The three most recent targets come from Lake Street, ATB Cormark, and Canaccord Genuity. Lake Street's Ryan Meyers reduced the target to $7 from $17 while retaining a Buy rating on October 20, 2026, pointing to softer pricing, an unfavorable product mix, and a slower path to margin improvement in adjusted EBITDA. On the same day, ATB Cormark's Frederico Gomes kept a Buy rating but lowered the target to $12 from $16. Canaccord Genuity maintains a Hold rating with an $8 target based on aggregator data. Averaging these figures yields the $9.00 central target.

The overall analyst consensus leans positive, with S&P Global classifying it as Strong Buy. Yet the broad $7-to-$12 spread and Canaccord's Hold rating indicate disagreement on the speed of any recovery in California's pricing environment. These targets are not guarantees.

Market Position and the Scale of the Required Move

After reaching a peak near $13.93 in mid-2026, GLAS has fallen sharply and recently traded around $1.90, close to its 52-week low of $1.67. Reaching $9.00 from current levels would require an advance of roughly 370%, a sizable gap. The company is not yet profitable on a trailing basis, so traditional P/E comparisons do not apply; instead, the market is reflecting uncertainty around future cash flows and margins in a competitive California wholesale setting. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Factors That Could Support Progress Toward the Target

Glass House stands out as one of the lower-cost producers in California through large-scale greenhouse operations and a 1.0 million-pound biomass target for 2026. If wholesale prices stabilize and volumes increase, operating leverage could support a higher valuation. A federal rescheduling of cannabis, which might ease the Section 280E tax burden, remains a frequently discussed potential catalyst. Even modest profitability could allow for multiple expansion in theory.

Obstacles That Could Limit Reaching the Target

Pricing remains the immediate challenge. The October pre-announcement highlighted softer pricing, an unfavorable product mix, and slower margin recovery—the same factors behind the recent target cuts. Persistent oversupply in California could keep wholesale prices low and margins compressed. Negative earnings, a market capitalization of roughly $150 million to $175 million, and the possibility of future share issuance to support operations add further considerations. Continued regulatory delays in Washington would also maintain the 280E tax impact.

Technical Levels to Watch

The 52-week low near $1.67 serves as the key support level; a break below it could point to additional weakness. On the upside, resistance appears in the $2.30-to-$2.60 zone where the stock consolidated before the October decline, with further supply overhead in the $3-to-$4 area. Closing the gap from above $6 down to $2 would require reclaiming considerable ground before the $9 target becomes more plausible from a technical standpoint.

Time Horizon and Items to Monitor

Analyst targets typically cover a roughly 12-month horizon, though assumptions differ. The next quarterly report, expected in mid-November, will be important for updated details on biomass, pricing, and margins. Investors should also track California wholesale price trends, any analyst revisions, federal rescheduling updates, and capital-raising activity. None of these provide certainty on the stock forecast direction.

Exploring AI Daily Buy/Sell Signals for Context

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical factors, and AI analysis. For volatile names like Glass House Brands, these signals can offer a structured way to assess the broader market outlook alongside fundamental work.

Personal Take on the $9 Target Scenario

In my view, the $9.00 central target—an average of three firm targets spanning $7 to $12—points to a roughly 370% move from levels near $1.90. The constructive case centers on low-cost production, volume growth, and policy developments, while the cautious case centers on ongoing pricing pressure, losses, and regulatory uncertainty. With analyst opinions spread across a wide range and the stock near multi-year lows, the target reflects a high-conviction recovery outlook rather than an imminent expectation. I’m watching the next earnings report, margin path, and policy signals closely before forming firmer conclusions.

Using Tickeron Tools in My Research

I often turn to Tickeron’s AI tools when evaluating situations like this one. The AI Daily Buy/Sell Signals platform helps me quickly scan for signals across volatile names and cross-check technical shifts against the fundamental picture. It has become a regular part of how I review opportunities without replacing deeper analysis. (Word count: 68)

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLAS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GLAS's Stochastic Oscillator sits in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 27 of 36 cases over the following month. The odds of a continued upward trend are 75%.

GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for GLAS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 10%. XERS experienced the highest price growth at 53%, while AKAN experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 10%. For the same stocks of the Industry, the average monthly volume growth was 21% and the average quarterly volume growth was 16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 3 (-100 ... +100)
Trend Prediction Engine 4